CRISPR Therapeutics COO to Step Down-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

CRISPR Therapeutics COO to Step Down

Mar 26, 2025 2:00 PM

04:38 PM EDT, 03/26/2025 (MT Newswires) -- CRISPR Therapeutics ( CRSP ) said late Wednesday that Chief Operating Officer Julianne Bruno will be stepping down from the company to pursue external opportunities, effective April 11.

Previous page： Addus HomeCare Starts Stock Offering; Shares Fall After-Hours Next page： --Pfizer Keeps Q3 Dividend at $0.42 a Share, Payable Sept. 3 to Holders of Record July 26

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Addus HomeCare Starts Stock Offering; Shares Fall After-Hours

Jun 26, 2024

04:36 PM EDT, 06/26/2024 (MT Newswires) -- Addus HomeCare ( ADUS ) said late Wednesday that it has commenced an offering of 1.5 million shares, with BofA Securities and Jefferies as book-running managers. The company expects to grant the underwriters a 30-day option to purchase up to 225,000 additional shares in the offering. Addus said it plans to use about...

--Pfizer Keeps Q3 Dividend at $0.42 a Share, Payable Sept. 3 to Holders of Record July 26

Jun 26, 2024

04:41 PM EDT, 06/26/2024 (MT Newswires) -- Price: 27.41, Change: -0.01, Percent Change: -0.04 ...

Markel Names Phil Schmidt as Chief Strategy Officer

Jun 26, 2024

04:41 PM EDT, 06/26/2024 (MT Newswires) -- Markel ( MKL ) said late Wednesday that it appointed, with immediate effect, Phil Schmidt as its chief strategy officer. The company said Schmidt joined Markel ( MKL ) in October as a managing director. Before Markel ( MKL ), Schmidt was a managing director for Burg, an investment bank. ...

Concentrix Fiscal Q2 Non-GAAP Earnings, Revenue Rise; Fiscal Q3, 2024 Guidance Set

Jun 26, 2024

04:40 PM EDT, 06/26/2024 (MT Newswires) -- Concentrix ( CNXC ) reported fiscal Q2 non-GAAP diluted earnings Wednesday of $2.69, up from $2.63 a year earlier. Analysts surveyed by Capital IQ expected $2.63. Revenue for the quarter ended May 31 was $2.38 billion, up from $1.61 billion a year earlier. Analysts polled by Capital IQ expected $2.35 billion. Concentrix (...